Home Blog Page 3

Real World Evidence Solutions Market High Growth Forecast 2021 Due to Rising Demand and Future Trends | Key companies: Iqvia, IBM, Pharmaceutical product development, Parexel, United Health Group, …

0

Reports Globe on the Global Business Report Real World Evidence Solutions Market aims to facilitate a thorough understanding of the definition, potential and scope of the market. The report is organized after extensive research and analysis by experts. It consists of an organized and methodical explanation of current market trends to help users to perform in-depth analysis of the market. The report includes a comprehensive assessment of various strategies such as mergers and acquisitions, product development, and research and development adopted by the major market leaders to stay in the global market.

In addition to providing users with significant value, the Reports Globe report focused on Porter’s five forces analysis to present the broad spectrum of opportunities, threats, and challenges in the market. Information extracted through various business models such as SWOT and PESTEL is represented as pie charts, diagrams and other images for better and faster understanding of facts.

The report provides an accurate and professional study of global business scenarios for the Real World Evidence Solutions market. The complex analysis of opportunities, growth factors and future forecasts are presented in simple and easy-to-understand formats. The report covers the real-world evidence solutions market by developing technology dynamics, financial standing, growth strategy, and product portfolio over the forecast period.

Get a FREE copy of this report with charts and graphs at: https://reportsglobe.com/download-sample/?rid=307235

The segmentation chapters allow the readers to understand aspects of the market such as its products, available technology, and applications. These chapters are written to describe their development over the years and the course they are likely to take in the years to come. The research report also provides detailed information on new trends that could define the development of these segments in the coming years.

Real World Evidence Solutions Market Segmentation:

Real World Evidence Solutions Market, By Application (2016-2027)

  • Pharmaceutical and medical device companies
  • Health care payers
  • Health care providers
  • Others

Real World Evidence Solutions Market, By Product (2016-2027)

  • Clinical data
  • Complaints data
  • Pharmacy data
  • Data fed by the patient

Major Players Operating in Real World Evidence Solutions Market:

  • Iqvia
  • IBM
  • Pharmaceutical product development
  • Parexel
  • Uni Health Group
  • Perkinelmer
  • Icon
  • Oracle
  • Competent
  • Syneos Health
  • Anthem
  • Clinigen
  • SAS Institute

Company Profiles – This is a very important section of the report which contains accurate and detailed profiles for the major players in the global Real World Proof Solutions Market. It provides information on core business, markets, gross margin, revenue, price, production, and other factors that define the market development of the players studied in the Real World Evidence Solutions Market report.

Global Real-World Evidence Solutions Market: Regional Segments

Different sections on regional segmentation give regional aspects of the Global Real World Evidence Solutions Market. This chapter describes the regulatory structure likely to have an impact on the entire market. It highlights the political landscape of the market and predicts its influence on the global real-world proof solutions market.

  • North America (United States, Canada)
  • Europe (Germany, United Kingdom, France, rest of Europe)
  • Asia Pacific (China, Japan, India, rest of Asia-Pacific)
  • Latin America (Brazil, Mexico)
  • Middle East and Africa

Get up to 50% off this report at: https://reportsglobe.com/ask-for-discount/?rid=307235

The objectives of the study are:

  1. To analyze the global Real World Evidence Solutions status, future forecast, growth opportunities, key market and major players.
  2. To present the development of Real World Evidence Solutions in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
  3. Draw up a strategic profile of the main players and analyze in depth their development plan and strategies.
  4. To define, describe, and forecast the market by product type, market applications, and key regions.

This report includes the market size estimate for Value (Million USD) and Volume (K units). Top-down and bottom-up approaches have been used to estimate and validate the market size of the Real World Evidence Solutions market, to estimate the size of various other dependent submarkets in the overall market. Major market players were identified by secondary research, and their market shares were determined by primary and secondary research. All percentages, divisions and distributions were determined using secondary sources and verified primary sources.

Some important points from the table of contents:

Chapter 1. Research methodology and data sources

Chapter 2. Executive summary

Chapter 3. Real-World Evidence Solutions Market: Industry Analysis

Chapter 4. Real-World Evidence Solutions Market: Product Information

Chapter 5. Real-World Evidence Solutions Market: Application Information

Chapter 6. Real-World Evidence Solutions Market: Regional Insights

Chapter 7. Real-World Evidence Solutions Market: Competitive Landscape

Ask your questions about personalization to: https://reportsglobe.com/need-customization/?rid=307235

How Reports Globe is different from other market research providers:

The creation of Reports Globe was supported by providing clients with a holistic view of market conditions and future possibilities / opportunities to derive maximum profit from their businesses and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and come up with the best possible solutions to meet your research needs.

Our Reports Globe team follows a rigorous data validation process, which allows us to publish editor reports with minimal or no deviation. Reports Globe collects, separates and publishes more than 500 reports per year covering products and services in many fields.

Contact us:

Mr. Mark Willams

Account manager

United States: + 1-970-672-0390

E-mail: [email protected]

Website: Reportsglobe.com


Source link

Gene therapy start-up already one of the largest manufacturers in its field … and in full expansion

0

Timothy Miller, CEO of Forge Biologics Inc. Photo: Columbus Business First

COLUMBUS, Ohio (COLUMBUS BUSINESS FIRST) – Although it has been around for a little over a year, Forge Biologics Inc. is already one of the top five such manufacturers in the growing field of gene therapy. .

And he’s starting an expansion next week that will likely propel him to the top.

The Drive Capital-backed startup has fielded a dozen clients, but raising a total of $ 160 million in venture capital to date has dramatically accelerated the schedule to build a lab space in a facility. of 175,000 square feet in Grove City, which once housed a motor vehicle. manufacturer’s warehouse and bookstore.

Four laboratories are operational and construction begins Monday on a row of seven laboratories, which will be followed by seven more according to market requirements.

“Forge is really on this inflection point of the hockey stick (of rapid growth upwards),” said co-founder and CEO Timothy Miller. “We are probably two to three years ahead of our competition. It’s not really the money, it’s the people.

Forge was launched in July 2020, in the midst of a pandemic, to create a dual model: the company develops gene therapies for rare and often fatal diseases, while also serving as a subcontractor for other researchers and pharmaceutical companies in the field. .

Revenue from manufacturing helps fuel the costly process of obtaining therapy through regulatory approval.

The company already has 115 employees and will likely surpass 200 in the coming year, Miller said.

Miller was previously CEO of Abeona Therapeutics Inc., a publicly traded gene therapy spinoff company of Nationwide Children’s Hospital.

Co-founder and COO Jaysson Eicholtz had led the manufacture of gene therapy at the Columbus Hospital. Erandi De Silva, the third co-founder and vice president of product development, had led program management at Myonexus Therapeutics, another Children’s spin-off acquired in 2019.

Perceptive Xontogeny Venture Fund led its first $ 40 million funding round and RA Capital Management led this spring’s $ 120 million Series B. Columbus-based Drive Capital LLC participated in both.

Gene therapy uses modified viruses – called vectors – to deliver copies of missing or defective genes to cells in the body. Forge chose to specialize in a particular vector called adeno-associated viruses or AAVs, which cannot replicate and do not cause any known human disease.

AAV is used in about 8% of all active gene therapy trials, according to the Journal of Gene Medicine, but an overview on the ground this year in the review Nature called it one of the most promising vectors.

But growing demand has created a bottleneck for manufacturing – researchers have to wait 18 to 24 months just for their production run to be queued.

By next year, Miller said, Forge will have the largest AAV production capacity of any contract manufacturer in the world. Shorter production times could mean getting life-saving treatments to market faster.

Forge Internal Therapy is licensed by the University of Pittsburgh for childhood Krabbe disease, a rare inherited condition that almost always kills before the age of 2 or 3. The therapy is given at the same time as a bone marrow transplant.

Andelyn Biosciences Inc., a children’s spin-off company, is also building a gene therapy manufacturing plant, but started out from a green field on the west campus of Ohio State University. Building inside an existing shell building allowed Forge to start operations faster, Eicholtz said.

Columbus-based BHDP Architecture designed the facility and Skanska, a Swedish company specializing in building the pharmaceutical industry, is the prime contractor.

“It’s been floating around in my head for a decade, wanting to build something like this,” Eicholtz said.

For more business news, visit ColumbusBusinessFirst.com.


Source link

NCGM, A Neuberg Diagnostics Company, Supports Implementation of Supplemental Newborn Screening for Duchenne Muscular Dystrophy in Boston Hospital

0

RALEIGH, North Carolina, August 6, 2021 / PRNewswire / – Enabled 06 august, CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, and Brigham and Women’s Hospital announced the first screening program for Duchenne muscular dystrophy (DMD), in a hospital environment.

Andy bhattacharjee, who directs NCGM, a Neuberg Diagnostics laboratory services company based in North Carolina, who serves and performs the Duchenne tests for the Brigham, said that “ultimately several hospitals or clinic sites in North America may be interested in the clinical trials program to serve their community. It’s a good example of how we need to conduct testing for patients and families, and raise awareness of innovations in the field for optimized newborn care and new models of healthcare delivery. It is essential that screening tests for the early detection of rare pediatric genetic diseases are now implemented in a hospital setting to fill the gaps, allow better monitoring and the use of evolving treatment practices. ”

Newborn screening for DMD in hospitals is an intermediate step (called additional screening) and can identify newborns with DMD by biochemical and molecular testing algorithm, which can start timely medical care. Elevated enzymatic activity of creatine kinase (CK) or levels of CK protein measured by immunoassays in the blood may establish a suspicion of DMD and next generation targeted sequencing (tNGS) can be used as a second level or confirmatory reflective test. The combined two-step algorithm can avoid test-related disparities and initiate timely diagnosis and treatment follow-up.

Media contact:
[email protected]
+1 252-371-1584

SOURCE Neuberg Center for Genomic Medicine


Source link

Spectrum Pharmaceuticals Receives Full Letter of Response from FDA for ROLONTIS® (eflapegrastim) | Company

0

HENDERSON, Nevada – (BUSINESS WIRE) – August 6, 2021–

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company specializing in innovative and targeted cancer therapies, today announced that it has received a Full Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the application for a biological product license (BLA) from the company for ROLONTIS® (éflapégrastim). CRL cited manufacturing deficiencies and indicated that re-inspection will be required. The company is seeking further clarification from the FDA and plans to meet with the agency as soon as possible.

“We are disappointed with this result and look forward to fully understanding the program remediation timelines,” said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We continue to believe in ROLONTIS and plan to diligently complete the regulatory process to bring ROLONTIS to market. “

About ROLONTIS

ROLONTIS is a novel long-acting granulocyte colony stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anticancer drugs. The ROLONTIS BLA is supported by data from two identically designed Phase 3 clinical trials, ADVANCE and RECOVER, which evaluated the safety and efficacy of ROLONTIS in 643 patients with early-stage breast cancer for the treatment of neutropenia due to myelosuppressive chemotherapy. In both studies, ROLONTIS demonstrated the predefined non-inferiority (NI) hypothesis of the duration of severe neutropenia (DSN) and a safety profile similar to that of pegfilgrastim. ROLONTIS also demonstrated non-inferiority to pegfilgrastim in the DSN over the 4 cycles (all NI p

AboutSpectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on the acquisition, development and commercialization of new and targeted oncology therapies. Spectrum has a strong track record of successfully executing the biopharmaceutical business model, from licensing and acquisition of differentiated drugs, to clinical development of new assets, to successful regulatory approvals and commercialization. in a competitive healthcare market. Spectrum has an advanced pipeline with new assets that meet unmet needs. This pipeline has the potential to transform the business in the near future. For more information on Spectrum Pharmaceuticals, please visit www.sppirx.com.

Notice Regarding Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These forward-looking statements relate to various matters, including, without limitation, statements relating to Spectrum’s business and its future, including the timing and outcome of the FDA re-inspection of the Hanmi bioplante in South Korea. , the timing and outcome of the company’s planned meeting with the FDA, including the company’s ability to remedy the cited deficiencies and the associated timeline, the overall likelihood of success, and the timeline for the ABL of the ‘business for ROLONTIS and the company’s ability to bring ROLONTIS to market, the future potential of Spectrum’s existing drug pipeline products, including ROLONTIS, and other statements that are not purely statements of historical fact. These forward-looking statements are made based on the current beliefs, understandings, expectations and assumptions of Spectrum’s management and are subject to significant risks and uncertainties that could cause actual results to differ materially from what can be expressed or understood. – understood in these forward-looking statements. Risks that could cause actual results to differ include, but are not limited to, the possibility that the different methodologies, assumptions and applications used by the Company to assess particular parameters of safety or efficacy may produce statistical results. different, and although the company believes the data collected from clinical trials of its product candidates, including poziotinib, is positive, that data may not be sufficient to warrant FDA approval; the possibility that the success of the first clinical trials, especially if they are based on a small sample of patients, will not lead to the success of the subsequent clinical trials, and other unforeseen events during the clinical trials which could lead to delays or other undesirable consequences; other uncertainties inherent in the development of new products; the possibility that Spectrum’s new and existing drug candidates, including poziotinib, may not ultimately prove to be safe or effective; the possibility that Spectrum’s new and existing drug candidates, if approved, may not be more effective, safer or more cost-effective than competing drugs; and other risks which are more fully described in the Company’s reports filed with the Securities and Exchange Commission (the “SEC”). The company does not intend to update these forward-looking statements and expressly disclaims any obligation to update the information contained in this press release, except as required by law. For more information about the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Spectrum’s business in general, see the risk information in the annual report on Spectrum’s Form 10-K for the fiscal year ended December 31, 2020, and in subsequent reports on Forms 10-K, 10-Q and 8-K and other documents filed with the SEC by Spectrum.

SPECTRUM PHARMACEUTICALS, INC. ® and ROLONTIS ®are registered trademarks of Spectrum Pharmaceuticals, Inc. and its subsidiary. REDEFINING CANCER CARE ™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

© 2021 Spectrum Pharmaceuticals, Inc. All rights reserved

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210806005079/en/

CONTACT: Robert Uhl

Managing Director, Westwicke ICR

858.356.5932

robert.uhl@westwicke.com Kurt Gustafson

Financial director

949.788.6700

Investor Relations@sppirx.com

KEYWORD: UNITED STATES NORTH AMERICA NEVADA

INDUSTRY KEYWORD: FDA BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Spectrum Pharmaceuticals

Copyright Business Wire 2021.

PUB: 06.08.2021 07:30 / DISC: 06.08.2021 07:32

http://www.businesswire.com/news/home/20210806005079/en

Copyright Business Wire 2021.


Source link

Global Generic Pharmaceuticals Market Trends, Strategies and Opportunities in Generic Pharmaceuticals Market 2021

0

Global Generic Pharmaceuticals Market Report 2021: Growth and Evolution of COVID-19 to 2030

The Business Research Company Global Generic Pharmaceuticals Market Report 2021: Growth and Evolution of COVID-19 to 2030

LONDON, GREATER LONDON, United Kingdom, August 6, 2021 /EINPresswire.com/ – According to the new ‘Generic Pharmaceuticals Global Market Report 2021: COVID-19 Growth And Change To 2030’ market research report released by The Business Research Company, the generic drug market is expected to grow from $ 233.66 billion in 2020 to $ 245.6 billion in 2021 at a compound annual growth rate (CAGR) of 5.1%. The growth is primarily driven by businesses resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, the remote work and closure of business activities which resulted in operational challenges. The generic pharmaceuticals market is expected to reach $ 331.54 billion in 2025 at a CAGR of 7.8%. One of the main drivers of the generic drug market is the growing incidence of chronic disease.

Sample request for Global Generic Pharmaceuticals Market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2479&type=smp

The generic pharmaceuticals market includes sales of generic pharmaceuticals. A generic drug is a drug designed to be identical to brand name drugs marketed by private companies in dosage form, strength, safety, route of administration, performance characteristics, quality and use. planned. Generic drugs work the same as brand name drugs in terms of clinical benefits. Generic drugs are manufactured after the exclusive rights or patent for brand name drugs expire. For example, some of the generic drugs in the generic pharmaceutical market include metformin, metoprolol, acarbose, acebutolol, aztreonam, and many more.

Global Generic Pharmaceuticals Market Trends
3D printing technology has the ability to transform drug manufacturing in the generic pharmaceutical market. 3D printed pharmaceuticals help improve R&D productivity and provide new benefits to patients. 3D printing allows the manufacturer to produce drugs with a custom size, shape and texture, which is not possible in traditional generic drug manufacturing. 3D printing can help the manufacturer make generic drugs that have different release dates, looks and tastes. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing was used to make tablets to treat Parkinson’s disease. Martin Wallace, director of GSK Technology, said GSK is investing in the benefits of 3D printing to make pills and tablets. In addition, the pharmaceutical company Aprecia has launched the “ZipDose” technology which manufactures 3D printed drugs.

Global generic pharmaceutical market segments:
The global generic pharmaceutical market is further segmented on the basis of therapy, distribution channel, type, drug administration, and geography.
By therapy: CNS, cardiovascular, dermatology, genitourinary / hormonal, respiratory, rheumatology, diabetes, oncology
By distribution channel: hospital pharmacies, retail pharmacies, online pharmacies
By type: biosimilar, single generic, super generic
By drug administration: oral, injectable, dermal / topical, inhaler
By Geography: The global generic pharmaceutical market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East, and Africa.

Learn more about the Global Generic Drugs Market Report at:
https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Generic Pharmaceuticals Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides global Generic Pharmaceuticals market overviews, analysis and forecast on market size and growth for the global Generic Pharmaceuticals market. Generic Pharmaceuticals, Global Generic Pharmaceuticals Market Share, Global Generic Pharmaceuticals Market Players, Global Generic Drugs Market Segments and Geographies, Revenue, Profiles and Market Share of Major Competitors of Generic Drugs Market. The Global Generic Pharmaceuticals Market report identifies key countries and segments for opportunities and strategies based on market trends and approaches of key competitors.

Read the 2021 Global Generic Pharmaceuticals Market Report from The Business Research Company for insight into the following:

Data segments: market size, global, by region and by country; Historical and forecast size, and growth rate for the world, 7 regions and 12 countries

Generic Pharmaceuticals Market Organizations Covered: Teva Pharmaceuticals, Mylan NV, Sandoz International GmbH, Hospira (Pfizer Inc.) and Sun Pharmaceutical.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, United States, South America, Middle East and Africa.

Country: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Interested in knowing more about The commercial research company?

The Business Research Company has published over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The reports are backed by 150,000 datasets, in-depth secondary research, and proprietary information from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 in various markets. Here is a list of reports from The Business Research Company similar to Generic Pharmaceuticals Global Market Report 2021:

Global Biologics Market Opportunities and Strategies – Global Forecast to 2023
https://www.thebusinessresearchcompany.com/report/biologics-market

Pharmaceuticals Market Opportunities and Strategies – Global Forecast to 2030
file: // C: Users RAJASEKHAR Downloads Pharmaceuticals Market – By Type (Pharmaceutical Drugs, Biologics), By Type of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatologic Drugs, Gastrointestinal Drugs, Genitourinary Drugs, Hematology Drugs , anti- Infectious drugs, Drugs against metabolic disorders, Mu

Global Pharmaceutical API Manufacturing Market Report 2021: Growth and Evolution of COVID-19 to 2030
https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The commercial research company
Email: info@tbrc.info
Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Olivier Guirdham
The commercial research company
+44 20 7193 0708
info@tbrc.info
Visit us on social networks:
Facebook
Twitter
LinkedIn



Source link

China Pharmaceutical Market and Healthcare Industry Analysis and Forecast Report 2021-2025 – ResearchAndMarkets.com

0

DUBLIN – (COMMERCIAL THREAD)–The “China Pharmaceutical and Healthcare Industry – Forecast and Analysis 2021” report was added to ResearchAndMarkets.com offer.

The COVID-19 pandemic has had a huge impact on China’s pharmaceutical and healthcare industry, as industry analysts expect a rapid return to normal demand levels.

China’s pharmaceutical and healthcare industry is one of the largest markets in the world, and it is fast becoming a leading global hub for drug innovation and development. Even as the COVID-19 crisis rages on, there is growing international investment in China’s pharmaceutical and healthcare sectors.

China’s healthcare and pharmaceutical landscape sees promising new healthcare reforms in the coming years as the government seeks to deliver quality healthcare to the growing demand of its people. On March 5, 2021, the government announced institutional health care reforms in line with China’s 14th Five-Year Plan (2021-2025).

The government has also highlighted a detailed roadmap to improve the overall quality of health care in the country while developing the necessary services in this sector. With generic drugs being the mainstay of the country’s population, generics made up nearly 65% ​​of the entire pharmaceutical industry in 2020.

While growth in the pharmaceutical industry is unlikely to return to pre-pandemic heights, China will continue to remain one of the largest markets for drug makers in the world.

The report covers the following data:

  • In-depth coverage of the pharmaceutical and healthcare industry in China by sectors along with an analysis of how the COVID-19 pandemic is affecting the industry.

  • We analyze the prescription drug, generic drug, over the counter drug segments and also analyze the medical research and clinical trial landscape in China.

  • A SWOT analysis of the Chinese pharmaceutical and healthcare industry.

  • A strategic analysis of Porter’s five forces on the Chinese pharmaceutical and healthcare industry is included, which examines the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and substitution of industry.

  • We take a close look at the regulatory framework governing the Chinese pharmaceutical and healthcare industry, and the challenges faced in terms of intellectual property rights. An analysis of China’s 14th Five-Year Health Care Reform Plan is also included in this section.

  • Competition in the industry, as well as an in-depth analysis of domestic and multinational industry players such as Shanghai Pharmaceuticals Holding, Sinopharm Group, Tasly Pharmaceutical Group, China Shijiazhuang Pharmaceutical Group, AstraZeneca, Eli Lilly (Lilly China), Novartis, and many more others are included.

Main topics covered:

A. Executive summary

B. Definition of industry

C. Brief overview of the pharmaceutical and healthcare sector APAC

D. Pharmaceutical and healthcare industry in China

D.1 Impact of COVID-19 on industry

D.2 Analysis of the pharmaceutical sector

D.3 Health sector analysis

D.4 Prescription drug market

D.5 Patented medicine market

D.6 Over-the-counter drugs market

D.7 Generic drug market

D.8 Medical research and clinical trials in China

E. Pharmaceutical and healthcare industry in China: SWOT analysis

E.1 Forces on which to build

E.2 Weaknesses to overcome

E.3 Opportunities to be exploited

E.4 Threats to be overcome

F. Chinese Pharmaceutical Industry: Analysis of Porter’s Five Forces Strategy

F.1 Overview

F.2 Bargaining power of buyers

F.3 Bargaining power of suppliers

F.4 Competitive Rivalry in Industry

F.5 Threat of new entrants

F.6 Threat of substitutes

G. Chronic medical conditions in China

G.1 Overview

G.2 Cancer

G.3 Chronic obstructive pulmonary disease

G.4 Diabetes

H. Industry regulatory framework

H.1 Presentation

H.2 China’s 14th Five-Year Health Care Reform Plan

H.3 Regulations governing over-the-counter drugs

H.4 Regulations governing biosimilars

H.5 Challenges with intellectual property rights

H.6 Challenges with counterfeit medicines

H.7 Pricing and reimbursement regime

H.8 Regulations governing the marketing of pharmaceutical products

I. Import / Export of pharmaceutical products in China

J. Competition in industry

J.1 Competitive landscape

J.2 Competition in generic drugs

J.3 Competition in the pharmaceutical sector

J.4 Competition in the distribution of medicines

K. Forecast: Pharmaceutical and healthcare industry in China

K.1 Prospects for the Chinese Pharmaceutical Industry

K.2 Prospects for the Chinese healthcare industry

K.3 Outlook for the prescription drug sector

K.4 Patented Medicines Market Outlook

K.5 OTC Drug Market Outlook

K.6 Generic Drugs Market Outlook

L. Main national and multinational actors

  • China Grand Pharmaceutical and Healthcare Holdings Ltd

  • China Resources Pharmaceutical Group Ltd.

  • Chinese pharmaceutical group Shijiazhuang

  • Harbin Pharmaceutical Group

  • Jiangsu Hengrui Medicine Co. Ltd.

  • Jiangsu Simcere Pharmaceutical Co. Ltd.

  • Luye Pharma Group Ltd.

  • Nanjing Pharmaceutical

  • North China Pharmaceutical Corporation

  • Shanghai Fosun Pharmaceutical (Group) Co Ltd

  • Shanghai Pharmaceuticals Holding Co.

  • Shijiazhuang Yiling Pharmaceutical Co Ltd

  • Sihuan Pharmaceutical Holdings Group Ltd.

  • Sino Biopharmaceutical Limited

  • Sinopharm Group

  • Sundia MediTech Co. Ltd.

  • Tasly Pharmaceutical Group

  • Zhejiang Hisun Pharmaceutical

  • AstraZeneca

  • Bayer Healthcare

  • Eli Lilly and Co. (Lilly China)

  • GlaxoSmithKline

  • Merck & Co.

  • Novartis

  • Pfizer

  • rock

  • Sanofi SA

For more information on this report, visit https://www.researchandmarkets.com/r/cavx5l


Source link

The Seratopical Revolution Skin Care Line From The Sera Labs Inc., A CURE Pharmaceutical Company, Will Be Available For Purchase This Fall From CVS, One Of The Leading National Drugstore Chains | National company

0

LOS ANGELES – (BUSINESS WIRE) – August 4, 2021–

Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that the six facial products of the Seratopic revolution The skincare line will be available for purchase from CVS in the fall of 2021. CVS is one of America’s leading national drugstore chains.

Seratopic revolution marries nature and science in a line of clean and nourishing beauty products. The range’s P3P complex, developed by CURE Pharmaceutical, injects natural, clean, herbal ingredients into the deep layers of the skin using a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as their delivery system, which dries out the skin incredibly, Seratopic revolution natural oil and surfactant delivery systems are very effective and provide almost immediate results.

Nancy Duitch, CEO of Sera Labs and Strategic Director of CURE Pharmaceutical, said: “There are many beauty companies out there, but the problem is most of them don’t understand that without an effective distribution system, products are on top of your skin and clog your pores. Our formulators have developed a proprietary high-tech delivery system that allows ingredients to penetrate deep into the skin. Our loyal customers will benefit from scientifically proven ingredients that are designed to improve hydration and rejuvenate collagen. Our Seratopic revolution facial products have these unique problem-solving attributes associated with beautiful packaging that stands out on the shelves and our partnership with one of the world’s most respected and recognized players: Nicole Kidman – as a strategic partner and Global Brand Ambassador – making our company and brand a fierce competitor in the beauty industry.

“This is another fantastic branding and expansion opportunity for our company and its product line. We created Seratopic revolution to meet the needs of a broad customer base, for all people of all skin types looking to explore truly innovative and cutting edge skin care product options. The fact that our skincare line is available at CVS for customers to buy strengthens our national presence and demonstrates the ever-growing support of retailers, ”said John Cammarano, senior vice president of marketing and sales at Sera. Labs.

Cammarano continued, “We have just started building our successful brand by leveraging multiple marketing channels that will not only build brand awareness, but always focus on ROI. Since there are many beauty companies available for retailers, we are delighted that CVS has given the Seratopic revolution product line a prime location for storage space and our products will reside between two of the world’s most recognized brands, giving our company the opportunity to acquire new customers and drive sales.

About CVS

CVS is the leading retail pharmacy in the United States with nearly 10,000 locations, including more than 1,700 pharmacies within Target and Schnucks grocery stores. We are committed to providing innovative healthcare solutions that create a simpler and more accessible experience for patients, clients and caregivers. CVS is the only national pharmacy to remove tobacco products from its shelves and has played a leadership role in the response to the COVID-19 pandemic by making testing and vaccinations available in locations across the United States. For the latest product and service offerings, visit www.cvs.com or download the CVS Pharmacy app.

About Sera Labs

Sera Labs ® is a trusted leader in the health, wellness and beauty industries of innovative products with cutting edge technology and superior ingredients such as CBD and clean herbal products. Sera Labs creates high quality products that use proprietary formulations based on science. Its more than 20 products are sold under the Seratopical ™ brands, and SeraLabs ™, Sera Labs sells its products at affordable prices, making them easily accessible globally. Strategically positioned in the growing beauty, health and wellness market categories. Sera Labs products are sold through major national pharmaceutical chains, grocery chains and mass retailers. The company also sells private label products to major retailers and multi-tier merchants, as well as consumer direct (DTC), through online orders on the website, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: press@theseralabs.com.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical ® is the pioneering developer of CUREform ™, a patented drug delivery platform that offers a number of unique immediate and controlled release drug delivery vehicles designed to improve efficacy, safety and effectiveness. patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot FDA registered and NSF® cGMP certified manufacturing facility enables it to partner with pharmaceutical and wellness companies around the world to a private and white label production. CURE has partnerships in the United States, China, Mexico, Canada, Israel and other markets in Europe.

Forward-looking statement

Statements that CURE makes in this press release may include statements that are not historical fact and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are generally identified by the use of words such as “anticipates”, “believes”, “believes”, “expects” to “,” intends to “,” may “,” “”, “plans”, “research”, “should”, “will” and variations of these words or similar expressions. CURE intends that such forward-looking statements be covered by the Safe Harbor for Forward-Looking Statements provisions contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for the purpose of comply with these Safe Harbor provisions.

These forward-looking statements include, without limitation, the ability to successfully market the products in partnership, the difficulty of predicting the timing or outcome of related research and development efforts, the characteristics and indications of the products in partnership, the authorizations marketing and launches of other products, the impact of regulation of the pharmaceutical industry, the impact of competitive products and prices, the acceptance and demand of new pharmaceuticals, the impact of patents and others property rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements contained in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intention or obligation to update these forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of our securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210804005409/en/

CONTACT: Media contact:

Monica M. Jaramillo, LABEL The Agency, mjaramillo @ labeltheagency.com Investor contact:

investisseur@curepharma.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: COSMETICS SUPERMARKET DETAIL SPECIALTY

SOURCE: Pharmaceutical CURE

Copyright Business Wire 2021.

PUB: 08/04/21 07: 00 / DISC: 08/04/21 07:02

http://www.businesswire.com/news/home/20210804005409/en



Source link

Seratopical Revolution Skincare Line from The Sera Labs Inc., a CURE pharmaceutical company, will be available for purchase this fall from CVS, one of the leading national drugstore chains.

0

LOS ANGELES, August 04, 2021– (BUSINESS WIRE) – Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced that the six facial products of the Seratopic revolution The skincare line will be available for purchase from CVS in the fall of 2021. CVS is one of America’s leading national drugstore chains.

Seratopic revolution marries nature and science in a line of clean and nourishing beauty products. The range’s P3P complex, developed by CURE Pharmaceutical, injects natural, clean, herbal ingredients into the deep layers of the skin using a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as their delivery system, which dries out the skin incredibly, Seratopic revolution natural oil and surfactant delivery systems are very effective and provide almost immediate results.

Nancy Duitch, CEO of Sera Labs and Strategic Director of CURE Pharmaceutical, said, “There are a lot of beauty companies out there, but the problem is, most of them don’t understand that without an effective distribution system, products sit on your skin and clog your pores. Our formulators have developed a proprietary high-tech delivery system that allows ingredients to enter deep into the skin. Our loyal customers will benefit from scientifically backed ingredients that are designed to enhance l hydration and rejuvenate collagen.Our Seratopic revolution facial products have these unique problem-solving attributes associated with beautiful packaging that stands out on the shelves and our partnership with one of the world’s most respected and recognized players: Nicole Kidman – as a strategic partner and Global Brand Ambassador – making our company and brand a fierce competitor in the beauty industry. “

“This is another fantastic branding and expansion opportunity for our company and its product line. We created Seratopic revolution to meet the needs of a broad customer base, for all people of all skin types looking to explore truly innovative and cutting edge skin care product options. The fact that our skincare line is available at CVS for customers to buy strengthens our national presence and demonstrates the ever-growing support of retailers, ”said John Cammarano, senior vice president of marketing and sales at Sera. Labs.

Cammarano continued, “We have just started building our successful brand by leveraging multiple marketing channels that will not only build brand awareness, but always focus on ROI. Since there are many beauty companies available for retailers to consider, we are delighted that CVS has given the Seratopic revolution product line a prime location for storage space and our products will reside between two of the world’s most recognized brands, giving our company the opportunity to acquire new customers and drive sales. “

About CVS

CVS is the leading retail pharmacy in the United States with nearly 10,000 locations, including more than 1,700 pharmacies within Target and Schnucks grocery stores. We are committed to providing innovative healthcare solutions that create a simpler and more accessible experience for patients, clients and caregivers. CVS is the only national pharmacy to remove tobacco products from its shelves and has played a leadership role in the response to the COVID-19 pandemic by making testing and vaccinations available in locations across the United States. For the latest product and service offerings, visit www.cvs.com or download the CVS Pharmacy app.

About Sera Labs

Will Labs® is a trusted leader in the health, wellness and beauty industries with innovative products featuring cutting edge technology and superior ingredients such as CBD and clean herbal products. Sera Labs creates high quality products that use proprietary formulations based on science. Its more than 20 products are sold under the Seratopical ™ brands, and SeraLabs ™, Sera Labs sells its products at affordable prices, making them easily accessible globally. Strategically positioned in the growing beauty, health and wellness market categories. Sera Labs products are sold through major national pharmaceutical chains, grocery chains and mass retailers. The company also sells private label products to major retailers and multi-tier merchants, as well as consumer direct (DTC), through online orders on the website, including opt-in subscriptions. For more information visit: Seratopicalrevolution.com, Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: press@theseralabs.com.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform ™, a patented drug delivery platform that offers a number of unique immediate and controlled release drug delivery vehicles designed to improve the efficacy, safety and experience of patients. patients for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square feet, registered with the FDA, NSF® The cGMP certified manufacturing facility allows it to partner with pharmaceutical and wellness companies around the world for private and white label production. CURE has partnerships in the United States, China, Mexico, Canada, Israel and other markets in Europe.

Forward-looking statement

Statements that CURE makes in this press release may include statements that are not historical fact and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and of Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are generally identified by the use of words such as “anticipates”, “believes”, “considers”, “s’ expects at “,” intends “,” may “,,” “projects”, “seeks”, “should”, “will”, and variations of such words or similar expressions. CURE intends that such forward-looking statements are covered by the Safe Harbor for Forward-Looking Statements provisions contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and makes this statement for the purpose of complying with those provisions of the safe harbor.

These forward-looking statements include, without limitation, the ability to successfully market the products in partnership, the difficulty of predicting the timing or outcome of related research and development efforts, the characteristics and indications of the products in partnership, the authorizations marketing and launches of other products, the impact of regulation of the pharmaceutical industry, the impact of competitive products and prices, the acceptance and demand of new pharmaceuticals, the impact of patents and others property rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements contained in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intention or obligation to update these forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of our securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210804005409/en/

Contacts

Media contact:
Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com

Investor contact:
investisseur@curepharma.com



Source link

Why you should supplement astaxanthin in addition to seafood *

0

Listen, salmon is always a solid food choice because it comes with so many other benefits and nutrients. But in terms of astaxanthin, it may not cut it. According to a report by the European Food Safety Authority, the the amount of astaxanthin in salmon varies quite dramatically. They found that farmed salmon and fish of all varieties had lower levels of antioxidants than those caught in the wild. Additionally, the type of fish is also important, with sockeye salmon having the most and arctic char, rainbow trout, and Atlantic salmon towards the bottom.

But let’s take the example of king salmon, which sits roughly in the middle with 0.54 mg of astaxanthin per 100 g of salmon fillet. If you wanted to consume 6 mg of astaxanthin (read: the dosage in the cellular beauty of mbg +, and the amount that can help support healthy skin function according to the latest clinical research*), you should eat about eleven 100 g (3.5 oz) salmon fillets per day. Not only is it, well, a lot of potentially expensive fish – it also exceeds the FDA recommended daily amount.

Also, you might be wondering if I can’t just get the antioxidant from somewhere else? Well, to answer that, we have to go back to where the antioxidant comes from. It is found naturally in the algae that salmon and other marine life feed on (such as shrimp, crabs, and lobster). In fact, that’s what gives these animals their peachy pink hue! But that’s also why wild-caught, non-farm-caught seafood is the only good dietary source of this superstar antioxidant.

But brands, like AstaReal® (source of mbg astaxanthin), can sustainably harvest this unique phytonutrient directly from the algae themselves (in this case, a green freshwater algae called Haematococcus pluvialis, a.k.a H. pluvialis). Not that small bonus: it means sourcing is a greener, more vegan alternative to seafood.


Source link

Mountain Valley MD Appoints Chief Medical Officer

0

TORONTO, Aug 03, 2021 (GLOBE NEWSWIRE) – Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce the appointment of Dr. Azhar Rana as the Company’s Medical Director (“Marketing director“).

Dr Rana brings to the Company nearly two decades of life sciences experience in clinical development, pre-launch and post-launch medical affairs, regulatory and business strategy, including 10 years of pharmaceutical leadership at Bristol Myers-Squibb. , Novo Nordisk and AstraZeneca.

During his pharmaceutical career, Dr. Rana has gained experience in the development, launch and lifecycle management of new therapies, leading and collaborating with teams in clinical operations and development, medical affairs. , regulatory affairs, quality and pharmacovigilance.

Dr. Rana created the North American Organization for Integrated Communications in Medical Health (imc Group), a globally recognized medical communications agency that supports pharmaceutical, biotechnology and medical device companies. As President and CEO, Dr Rana has led a large cross-functional medical marketing team, working with global companies and healthcare professionals at various stages of drug and device development. He brings extensive experience in a number of pathological fields including virology, oncology, inflammation and metabolic diseases.

Dr Rana received her medical degree from Aga Khan University and subsequently trained in internal medicine in the UK.

“I am extremely proud to welcome Dr. Rana to our leadership team at Mountain Valley MD and look forward to his immediate contribution to advancing our pipeline of new health and wellness applications,” said Dennis Hancock, President and CEO of Mountain Valley MD. “Dr. Rana’s extensive pharmaceutical and biotech experience comes at a critical time for MVMD as we continue to advance our science and solidify key technology license agreements.

The Company granted 1,000,000 options to Dr. Rana at an exercise price of $ 0.365 per share. The options are exercisable for a period of five years, 20% vest on the grant date, 30% on the 6-month anniversary following the grant date and the remaining 50% on the 12-month anniversary following the grant date. the date of grant.

“I am thrilled to join MVMD and look forward to working with the excellent management team here to help advance the many technology applications to commercialization in this next phase of planned growth,” said Dr. Rana. “The pursuit of the Company’s broad vision of more life across the global landscape is very compelling to me personally at this point in my career and I am honored that my legacy is working to support broad animal husbandry and human health initiatives. “

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC
Mountain Valley MD is building a world-class biotechnology and life sciences company focused on the implementation of its patented Quicksome ™ oral drug formulation and delivery technologies and Quicksol ™ solubilization technology for macrocyclic lactones, in order to innovate cutting-edge products that are sought after around the world. .

MVMD’s proposal to provide Quicksome ™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is central to the company’s success in key health and wellness categories. In keeping with its vision of “helping people live their best lives”, MVMD applies its Quicksome ™ and Quicksol ™ technologies to its groundbreaking work for advanced vaccine and pharmaceutical drug delivery as well as product development for drug management. pain, weight loss, energy, focus, sleep, anxiety and more.

The company’s patented Quicksome ™ desiccation technology uses advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly effective product formats that are consumed orally. The result is a new generation of product formulations capable of delivering vaccines, drugs and nutraceuticals to the body faster, with increased impact, efficiency and precision.

The Company’s patented Quicksol ™ solubilization technology covers all highly solubilized macrocyclic lactones (including the drugs Ivermectin and Selamectin). MVMD’s solubility technology applied to the drug Ivermectin is the only form in the world that uses only excipients currently approved by the United States Food and Drug Administration (FDA), making it a prime candidate for the drug. human injection and sublingual applications as well as much broader treatments for animal husbandry and pets due to its low viscosity.

For more information about the company and its contact details, visit www.mountainvalleymd.com.

SOURCE: Mountain Valley MD Holdings Inc.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this press release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “could”, “will”, “the”. intention ”,“ should ”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.

The actual results of the Company could differ materially from those anticipated in this forward-looking information due to regulatory decisions, competitive factors in the industries in which the Company operates, economic conditions and other factors, many of which are beyond the scope of to the control of the company.

The Company makes forward-looking statements regarding the appointment of Dr. Rana. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that such expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this press release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.


        


Source link